Peptide

ARA-290

Also known as

Cibinetide · pHBSP · PHBSP · pyroglutamate helix B surface peptide · Pyroglutamate HBSP · ARA 290 · ARA290 · Helix B surface peptide · pGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser

Community talk. May contain inaccuracies. Not medical advice. Not a protocol. Not for human or animal use.

What it is

Identity	Cibinetide, an EPO-derived research peptide discussed for neuropathy: burning, tingling and reduced sensation.
Research purpose	Designed around tissue-protection signaling without the intended blood-building action of EPO; nerve repair remains a research goal.

Notes

ARA-290, also called cibinetide, is an EPO-derived research peptide discussed for burning, tingling and reduced sensation from neuropathy. People hope for nerve repair as well as pain relief; opened accounts include improvement, no benefit and painful flares.

An 11-amino-acid peptide designed around tissue-protection signaling. It was engineered from erythropoietin, the hormone involved in red-cell production, to activate the innate repair receptor without the intended blood-building action. Small-fiber neuropathy means damage to tiny nerves involved in sensation and pain; the repair mechanism does not establish a cure. Brines et al. — ARA 290 in type 2 diabetes and neuropathic symptoms (Official context · Accessed 2026-09-30) · Culver et al. — Cibinetide improves corneal nerve fiber abundance (Official context · Accessed 2026-09-30)

Source context — Brines et al. — ARA 290 in type 2 diabetes and neuropathic symptoms: Formal disease-population trial; not home-product evidence or a regimen. Volunteer kinetics quoted from a separate source, not measured in these patients. Serious-event causal assessments are mixed. Publisher dates the article 2014; PubMed lists 2015 issue metadata.

Source context — Culver et al. — Cibinetide improves corneal nerve fiber abundance: Abstract inspected, not full text. Sarcoidosis population and surrogate nerve markers; pain placebo response and nonsignificant subgroup contrast preserved. No proof of durable cure or combo benefit.

What people notice

Less discomfort	One logger described less foot tightness and easier barefoot walking. Another noticed returning temperature and sensation after iron had already eased tingling.
No benefit	Separate reports describe no relief at day 14, after two month-long attempts, or after 60 days.
Worse symptoms	One writer developed painful heel pins-and-needles at 2–4 mg/day and stopped after five days; that does not establish nerve repair.

Notes

Less constriction, numbness and pain from ordinary contact. An SFN logger described less meal-associated discomfort, less tape-like foot tightness and easier barefoot walking. These were feelings, not measured regeneration. Effectiveness of ARA-290...My Assessment — original log and follow-ups (Community discussion · Accessed 2026-09-30)

Regaining sensation can matter as much as reducing pain. Another writer noticed temperature and feeling returning to the feet. Iron treatment had already reduced tingling, and SFN was not confirmed. The benefit is worth recording without using it to diagnose the condition. Do I have SFN? ARA-290 helped (Personal report · Accessed 2026-09-30)

No relief at day 14 also belongs here. A separate SFN writer explicitly confirmed 4 mg/day and later stopped. Their later diagnostic change underscores that matching a popular amount does not guarantee a response. ARA 290 14 days in, no relief (Community discussion · Accessed 2026-09-30)

Four-week blocks are discussed; the right repeat interval is unresolved. One PeptideForum author asked how long to wait after 28 days. Replies include no benefit after two month-long 4–8 mg/day attempts and after 60 days at 4 mg/day; routes were unstated. Longer exposure does not settle the response question. ARA290 — repeat interval question and differing outcomes (Community discussion · Accessed 2026-09-30)

Worse pins-and-needles is not proof of nerve repair. A Sjögren's/SFN writer increased from 0.5 to 4 mg/day, developed painful heel symptoms at 2–4 mg and stopped after five days. A later attempt felt more tolerable after gabapentin changed; causation and the repair explanation remain unproven. ARA-290 Nerve regeneration — painful flare and later reattempt (Personal report · Accessed 2026-09-30)

Source context — Effectiveness of ARA-290...My Assessment — original log and follow-ups: Self-reports; OP acknowledges TRT/deca/GH co-use. Nasal reply concerns another condition and a combination. Dose escalation, safety assurance, sourcing and preparation claims rejected. Later duplicate retellings are not independent users.

Source context — Do I have SFN? ARA-290 helped: SFN unconfirmed; dose unstated; iron and other diagnostic issues confound attribution. Improvement cannot diagnose SFN or prove regeneration. No exact onset/offset interval supplied.

Source context — ARA 290 14 days in, no relief: Severe complex history and later self-reported genetic diagnosis; no controlled comparison. No-side-effects and tolerance-reset explanations in replies are not accepted. Same author elsewhere is not a new independent report.

Source context — ARA290 — repeat interval question and differing outcomes: Routes absent from numerical replies; conditions differ. Some writers may also appear in other opened threads; no unique-user tally. Knee-relief timing is not a neuropathy measurement or a clearly specified one-dose window.

Source context — ARA-290 Nerve regeneration — painful flare and later reattempt: Self-reported Sjögren's/SFN/allodynia and uncertain product. Later treatment changes confound comparison. Author's inference that symptoms prove activation or that trial participants lacked allodynia is not adopted.

Doses people talk about

Trial-mirroring log	4 mg/day under the skin for 28 days, with 8 mg/day for the final two days in that same account.
Longer stacked account	1 mg on five days each week for six months, then every other day, alongside KPV and Thymosin Alpha-1; route unspecified.
Other saved amounts	Separate notes include roughly 2 mg starts followed by 4 mg, about 6 mg daily, and 2 mg under the skin twice or three times weekly.

Notes

4 mg/day SubQ for 28 days: an explicitly trial-mirroring log. The author reported thigh injections, then 8 mg/day for the final two days. That individual escalation does not establish a dose-response rule. Effectiveness of ARA-290...My Assessment — original log and follow-ups (Community discussion · Accessed 2026-09-30)

1 mg on five days each week: a different, stacked account. A long-Covid/SFN commenter reported this for six months, then every other day, alongside KPV and Thymosin Alpha-1. Route was unspecified; it is not an equivalent exposure to daily SubQ use. ARA-290, whats your experience? (Community discussion · Accessed 2026-09-30)

Other recorded schedules remain separate. Earlier notes include roughly 2 mg starts followed by 4 mg, about 6 mg daily, commercial 2 mg SubQ twice weekly, and 2 mg SubQ three times weekly. Microgram marketing charts also appear; none establishes a validated substitute or dose threshold.

Source context — ARA-290, whats your experience?: Route unstated in selected numerical reports; 4 mg frequency not explicitly stated. Different causes, unverified diagnoses and stacked use. Units-only amounts are not converted. Procurement/recipe comments excluded.

Half-life, onset & duration

Felt onset	Day 12–13 in the original SFN log; other accounts describe day-five change or two months in a stack.
Felt duration	No reliable after-dose window. Some report symptoms returning quickly after stopping; the original logger later reported loss of benefit after seven months of use.
Half-life	About 20 minutes after 4 mg under the skin in cited volunteer research. Circulated summaries distinguish about 2 minutes IV from 20–30 minutes under the skin.

Notes

Day 12–13 in the original SFN log. Relief arrived after an initially quiet period, then plateaued. Other accounts differ. Effectiveness of ARA-290...My Assessment — original log and follow-ups (Community discussion · Accessed 2026-09-30)

Day five and two months describe different experiences. A bulging-disc commenter reported early change around day five at 4 mg, with frequency unstated. The 1 mg/KPV/TA-1 commenter placed pain cessation at two months. Neither establishes when ARA-290 alone starts working. ARA-290, whats your experience? (Community discussion · Accessed 2026-09-30)

Return of symptoms after stopping is reported, but not with one reliable clock. The temperature-sensation writer said symptoms returned quickly after running out. A knee-osteoarthritis commenter described relief diminishing within a couple of days; that different condition cannot define a neuropathy duration. Do I have SFN? ARA-290 helped (Personal report · Accessed 2026-09-30) · ARA290 — repeat interval question and differing outcomes (Community discussion · Accessed 2026-09-30)

Seven months of benefit during use is not a single-dose duration. The logger later reported loss of effect and ultimately found gabapentin more effective. This qualifies the early success. Effectiveness of ARA-290...My Assessment — original log and follow-ups (Community discussion · Accessed 2026-09-30)

The diabetes paper cites separate volunteer kinetics. Its Methods reports roughly 20 minutes terminal plasma half-life after 4 mg SubQ in healthy volunteers. The neuropathy trial did not newly measure that value in its patients; its 28-day dosing plus 28-day follow-up does not specify an individual's relief duration. Brines et al. — ARA 290 in type 2 diabetes and neuropathic symptoms (Official context · Accessed 2026-09-30)

About 2 minutes IV versus 20–30 minutes SubQ is circulated trial-derived context. Jacked Forums repeats these plasma figures; they are formal-research summaries, not users measuring elimination. Half-life means the measured amount halves, not that pain relief ends then. Jacked Forums ARA-290 compound guide (Community guide · Accessed 2026-09-30)

Source context — Jacked Forums ARA-290 compound guide: Forum-hosted editorial guide, not a first-person log. Half-life is underlying formal-PK lore, not a new community measurement; calculator, no-clot-risk assurance and dose recommendations not adopted. Publication date unavailable.

Cycles people discuss

Four-week blocks	28-day blocks, roughly 28 days observing off, symptom-led repeats and continuous months are discussed; no repeat interval is established.

Notes

A month on, a month observing is trial-derived forum logic. The original notes preserve 28-day blocks, roughly 28 days off, symptom-led repeats and months of continuous use. None establishes a necessary break, a tolerance reset or long-term safety. Morning-versus-evening benefit also remains unsettled.

Stacks

Repair-stack discussion	BPC-157, TB-500 and KPV appear in community pairings; no controlled combination benefit is established.
KPV and TA-1	The long-term 1 mg account also used KPV and Thymosin Alpha-1, so its reported improvement cannot be assigned to ARA-290 alone.
Intranasal combination	One reply described 5 mg/week ARA-290 plus about 15 mg/week GHK-Cu intranasally and roughly 12 hours of combined relief; absorption was unverified.

Notes

Stacks and other treatment changes blur credit. One commenter taking 4 mg ARA-290 credited tirzepatide and reduced alcohol use more than ARA-290. The original notes also retain BPC-157, TB-500 and KPV pairings, background neuropathy medicines, footwear, pacing and activity changes. No controlled stack benefit is established. Anyone tried ARA 290 (Community discussion · Accessed 2026-09-30)

BPC-157: Most common community pairing for “structural repair + nerve/IRR” storytelling; no controlled combo data; attribution of any win is confounded. [community]

TB-500 / TB4 fragments: Occasional third leg in “repair stacks” with BPC; systemic recovery lore, not SFN-trial-based. [community]

KPV: Discussed in some pain/inflammation peptide guides as NF-κB / gut-inflammation adjacency alongside ARA-290 — pure community theory. [community]

Nasal anecdotes describe a different experiment. One reply described intranasal ARA-290 at 5 mg/week plus GHK-Cu around 15 mg/week, with roughly 12 hours of combined relief. Absorption and each compound's contribution remain unverified. Effectiveness of ARA-290...My Assessment — original log and follow-ups (Community discussion · Accessed 2026-09-30)

Source context — Anyone tried ARA 290: Self-reported peripheral neuropathy cause; co-treatment and behavior change. Improvements are principally attributed by the writer to tirzepatide, not transferred to ARA-290.

Watch for

Pain flares	Worse pins-and-needles is not proof of healing; one later retry also involved a gabapentin change.
Other complaints	Injection irritation, headache, fatigue, dizziness and stomach upset are recorded. Vial identity, sterility and concentration remain concerns.
Safety limits	Short trials do not settle long-term risk. Serious events occurred in the diabetes study, with differing relatedness assessments; orphan designation is not approval.

Notes

Product uncertainty and interaction gaps remain practical concerns. Original reports include injection-site irritation, headache, fatigue, dizziness and stomach upset. Research-vial identity, sterility and concentration are uncertain; interactions and years of use are poorly mapped. A normal blood panel cannot settle these questions.

Short trial reassurance is not zero risk. The diabetes paper recorded four serious events in the active arm, two initially judged possibly related. Renal worsening involved increased furosemide; a later cellulitis/fatal-heart-attack event was judged unrelated by the safety committee. Those assessments neither prove causation nor establish safety outside trials. Brines et al. — ARA 290 in type 2 diabetes and neuropathic symptoms (Official context · Accessed 2026-09-30)

Orphan designation is not approval. FDA's sarcoidosis-neuropathic-pain designation record lists this peptide as not approved for that orphan indication. FDA orphan designation 349111 — sarcoidosis neuropathic pain (Official context · Accessed 2026-09-30)

Source context — FDA orphan designation 349111 — sarcoidosis neuropathic pain: Verifies this designation and indication's listed status; not a certification of worldwide legality, manufacturing quality or every possible indication.

Full notes

What ARA-290 is

An 11-amino-acid peptide designed around tissue-protection signaling. It was engineered from erythropoietin, the hormone involved in red-cell production, to activate the innate repair receptor without the intended blood-building action. Small-fiber neuropathy means damage to tiny nerves involved in sensation and pain; the repair mechanism does not establish a cure. Official context Official context
Orphan designation is not approval. FDA's sarcoidosis-neuropathic-pain designation record lists this peptide as not approved for that orphan indication. Official context

What people hope to notice

Less constriction, numbness and pain from ordinary contact. An SFN logger described less meal-associated discomfort, less tape-like foot tightness and easier barefoot walking. These were feelings, not measured regeneration. Reddit / r/smallfiberneuropathy
Regaining sensation can matter as much as reducing pain. Another writer noticed temperature and feeling returning to the feet. Iron treatment had already reduced tingling, and SFN was not confirmed. The benefit is worth recording without using it to diagnose the condition. Personal report
Relief may feel like a more usable day, rather than a high. The preserved community account describes little acute psychoactive effect and occasional better sleep as night pain eases. This is different from a sedative effect or a predictable immediate sensation. Community

Doses people discuss

Reported amounts describe discussion, not instructions. SubQ means injection under the skin; IV means into a vein. Routes are not interchangeable.

4 mg/day SubQ for 28 days: an explicitly trial-mirroring log. The author reported thigh injections, then 8 mg/day for the final two days. That individual escalation does not establish a dose-response rule. Reddit / r/smallfiberneuropathy
1 mg on five days each week: a different, stacked account. A long-Covid/SFN commenter reported this for six months, then every other day, alongside KPV and Thymosin Alpha-1. Route was unspecified; it is not an equivalent exposure to daily SubQ use. Reddit / r/neuropathy
Other recorded schedules remain separate. Earlier notes include roughly 2 mg starts followed by 4 mg, about 6 mg daily, commercial 2 mg SubQ twice weekly, and 2 mg SubQ three times weekly. Microgram marketing charts also appear; none establishes a validated substitute or dose threshold. Community

Half-life claims in community guides

About 2 minutes IV versus 20–30 minutes SubQ is circulated trial-derived context. Jacked Forums repeats these plasma figures; they are formal-research summaries, not users measuring elimination. Half-life means the measured amount halves, not that pain relief ends then. Community guide
A two-minute claim without its route can mislead. The commercial MuscleChemistry repost gives that figure without a route in its FAQ. It cannot establish a two-minute SubQ half-life or a reason to repeat doses. MuscleChemistry forum

When people first notice a change

Day 12–13 in the original SFN log. Relief arrived after an initially quiet period, then plateaued. Other accounts differ. Reddit / r/smallfiberneuropathy
Day five and two months describe different experiences. A bulging-disc commenter reported early change around day five at 4 mg, with frequency unstated. The 1 mg/KPV/TA-1 commenter placed pain cessation at two months. Neither establishes when ARA-290 alone starts working. Reddit / r/neuropathy
No relief at day 14 also belongs here. A separate SFN writer explicitly confirmed 4 mg/day and later stopped. Their later diagnostic change underscores that matching a popular amount does not guarantee a response. Reddit / r/smallfiberneuropathy

How long reported relief lasts

Return of symptoms after stopping is reported, but not with one reliable clock. The temperature-sensation writer said symptoms returned quickly after running out. A knee-osteoarthritis commenter described relief diminishing within a couple of days; that different condition cannot define a neuropathy duration. Personal report Reddit / r/PeptideForum
Seven months of benefit during use is not a single-dose duration. The logger later reported loss of effect and ultimately found gabapentin more effective. This qualifies the early success. Reddit / r/smallfiberneuropathy

Courses and breaks people describe

Four-week blocks are discussed; the right repeat interval is unresolved. One PeptideForum author asked how long to wait after 28 days. Replies include no benefit after two month-long 4–8 mg/day attempts and after 60 days at 4 mg/day; routes were unstated. Longer exposure does not settle the response question. Reddit / r/PeptideForum
A month on, a month observing is trial-derived forum logic. The original notes preserve 28-day blocks, roughly 28 days off, symptom-led repeats and months of continuous use. None establishes a necessary break, a tolerance reset or long-term safety. Morning-versus-evening benefit also remains unsettled. Community

What to watch for

Worse pins-and-needles is not proof of nerve repair. A Sjögren's/SFN writer increased from 0.5 to 4 mg/day, developed painful heel symptoms at 2–4 mg and stopped after five days. A later attempt felt more tolerable after gabapentin changed; causation and the repair explanation remain unproven. Personal report
Short trial reassurance is not zero risk. The diabetes paper recorded four serious events in the active arm, two initially judged possibly related. Renal worsening involved increased furosemide; a later cellulitis/fatal-heart-attack event was judged unrelated by the safety committee. Those assessments neither prove causation nor establish safety outside trials. Official context
Product uncertainty and interaction gaps remain practical concerns. Original reports include injection-site irritation, headache, fatigue, dizziness and stomach upset. Research-vial identity, sterility and concentration are uncertain; interactions and years of use are poorly mapped. A normal blood panel cannot settle these questions. Community

What the community accounts add

Nasal anecdotes describe a different experiment. One reply described intranasal ARA-290 at 5 mg/week plus GHK-Cu around 15 mg/week, with roughly 12 hours of combined relief. Absorption and each compound's contribution remain unverified. Reddit / r/smallfiberneuropathy
Cost shapes how people judge a course. The 2022 estimate was $600–700/month at 4 mg/day. Prices change; a later nonresponder also stopped because of expense. Reddit / r/smallfiberneuropathy Reddit / r/PeptideForum
Stacks and other treatment changes blur credit. One commenter taking 4 mg ARA-290 credited tirzepatide and reduced alcohol use more than ARA-290. The original notes also retain BPC-157, TB-500 and KPV pairings, background neuropathy medicines, footwear, pacing and activity changes. No controlled stack benefit is established. Reddit / r/neuropathy Community
A null result is not automatically too little peptide. The 4 mg/day SFN nonresponder contrasts with lower-amount positive stack accounts. Forum claims that anything below 2 mg is ineffective, or that more always helps, do not explain that disagreement. Reddit / r/smallfiberneuropathy Reddit / r/neuropathy Community

The research behind the repair story

Nerve markers improved without a clear universal pain result. The 64-person sarcoidosis trial compared 1, 4 and 8 mg/day for 28 days. Corneal and regenerating skin-fiber results favored 4 mg; pain also improved with placebo. This supports research interest, not a cure or a higher-is-better rule. Official context
The diabetes paper cites separate volunteer kinetics. Its Methods reports roughly 20 minutes terminal plasma half-life after 4 mg SubQ in healthy volunteers. The neuropathy trial did not newly measure that value in its patients; its 28-day dosing plus 28-day follow-up does not specify an individual's relief duration. Official context